Status:
RECRUITING
REBECCA Real-world Early BrEast CanCer mAnagement
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Detailed Description
The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
December 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2028
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT06856343
Start Date
December 30 2024
End Date
January 31 2028
Last Update
January 21 2026
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Agen, France
2
Research Site
Argenteuil, France
3
Research Site
Avignon, France
4
Research Site
Beauvais, France